INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5501, 0, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5502, 0, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5503, 0, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5504, 0, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5505, 0, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5506, 0, 'Colesevelam', 'Diabetic Ketoacidosis', 'Colesevelam should not be used for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5507, 0, 'Colesevelam', 'Gastrointestinal Diseases', 'The manufacturer considers colesevelam contraindicated in patients with a history of bowel obstruction.  Because of its constipating effects, colesevelam is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction.  Because of the tablet size, colesevelam tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5508, 0, 'Colesevelam', 'Hyperlipoproteinemias', 'The manufacturer considers the use of colesevelam to be contraindicated in patients with TG levels >500 mg/dL.  Colesevelam, like other bile acid sequestrants, can increase serum TG concentrations.  Lipid parameters, including TG levels and non-HDL-C, should be obtained before starting colesevelam and periodically thereafter.  Caution should be exercised when treating patients with TG levels greater than 300 mg/dL.  Colesevelam should be discontinued if TG levels exceed 500 mg/dL or if the patient develops hypertriglyceridemia-induced pancreatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5509, 0, 'Colesevelam', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5510, 0, 'Colesevelam', 'Malabsorption Syndromes', 'Bile acid sequestrants, including colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K.  Caution should be exercised when treating patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins.  The manufacturer recommends to instruct patients taking colesevelam and oral vitamin supplementation to take their vitamins at least 4 hours prior to colesevelam.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5511, 0, 'Alfuzosin', 'Hepatic Insufficiency', 'Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C).  The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5512, 0, 'Alfuzosin', 'Long QT Syndrome', 'Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5513, 0, 'Alfuzosin', 'Kidney Diseases', 'Caution should be exercised when alfuzosin is administered in patients with severe renal impairment as safety data is limited on these patients (CrCl < 30 mL/min).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5514, 0, 'Alfuzosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5515, 0, 'Alfuzosin', 'Cataract', 'Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with antiadrenergic agents.  If a patient is undergoing cataract surgery, the ophthalmologist should be prepared for possible modifications of the surgical technique (iris hooks, iris dilator rings).  There does not appear to be a benefit in stopping antiadrenergic agents therapy prior to the cataracts surgery.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5516, 0, 'Conestat alfa', 'Thromboembolism', 'Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of plasma derived conestat alfa.  Patients with risk factors such as, prior history of thrombosis might be at an increased risk.  It is recommended to monitor patients with known risk factors for TE events during and after therapy administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5517, 0, 'Corticotropin', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of adrenocorticotropic agents may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if adrenocorticotropic therapy is administered to these patients.  During prolonged use, tuberculosis chemoprophylaxis may be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5518, 0, 'Corticotropin', 'Adrenal Insufficiency', 'The use of adrenocorticotropic agents is contraindicated in patients with primary adrenocortical insufficiency because of the lack of adrenal responsiveness.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5519, 0, 'Corticotropin', 'Water-Electrolyte Imbalance', 'Adrenocorticotropic agents may cause hypernatremia, hypokalemia, hypocalcemia, and fluid retention.  Therapy with these agents, particularly if intended for longer than brief periods, should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5520, 0, 'Corticotropin', 'Peptic Ulcer Perforation', 'Adrenocorticotropic agents may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5521, 0, 'Corticotropin', 'Adrenocortical Hyperfunction', 'The use of adrenocorticotropic agents is contraindicated in patients with adrenocortical hyperfunction.  These agents stimulate the release of cortisol and aldosterone and may aggravate symptoms of hyperadrenocorticism.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5522, 0, 'Corticotropin', 'Infections', 'The immunosuppressant and anti-inflammatory effects of adrenocorticotropic agents, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, adrenocorticotropic agents should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  For patients who have received prolonged adrenocorticotropic therapy who develop a severe or life-threatening infection, supplemental doses of rapid-acting corticosteroids may be required, since these patients may have hypothalamic-pituitary insufficiency.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5523, 0, 'Corticotropin', 'Keratitis, Herpetic', 'Adrenocorticotropic agents should be used cautiously, if at all, in patients with ocular herpes simplex because of the risk of corneal perforation.  The manufacturers consider their use to be contraindicated in such setting.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5524, 0, 'Corticotropin', 'Osteoporosis', 'Adrenocorticotropic agents inhibit the absorption of intestinal calcium and increase urinary excretion of calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of these agents, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose adrenocorticotropic therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  The manufacturers consider the use of adrenocorticotropic agents to be contraindicated in such setting.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5525, 0, 'Corticotropin', 'Peptic Ulcer', 'Adrenocorticotropic agents may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  Delayed healing of peptic ulcers has also been reported.  Therapy with adrenocorticotropic agents, if necessary, should be administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  The manufacturers consider their use to be contraindicated in such setting.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5526, 0, 'Corticotropin', 'Scleroderma, Localized', 'The use of adrenocorticotropic agents is contraindicated in patients with scleroderma.  Adrenocorticotropic agents may precipitate renal crisis with malignant hypertension in these patients, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  If treatment is required for inflammatory myositis or pericarditis, glucocorticoids are preferable because of their more predictable pharmacologic effect.  However, glucocorticoids should also be avoided in the long-term treatment of patients with scleroderma for similar reasons.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5527, 0, 'Corticotropin', 'Fibrosis', 'Adrenocorticotropic agents may have enhanced effects in patients with cirrhosis.  Dosage adjustments may be necessary in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5528, 0, 'Corticotropin', 'Psychotic Disorders', 'Adrenocorticotropic agents may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during adrenocorticotropic therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5529, 0, 'Corticotropin', 'Diabetes Mellitus', 'Adrenocorticotropic agents may impair glucose tolerance and cause hyperglycemia.  Therapy with these agents should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during adrenocorticotropic therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5530, 0, 'Corticotropin', 'Ocular Hypertension', 'Prolonged use of adrenocorticotropic agents may cause elevated intraocular pressure and glaucoma with possible damage to the optic nerves.  Long-term therapy with these agents should be administered cautiously in patients with preexisting glaucoma (particularly open-angle glaucoma) or increased intraocular pressure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5531, 0, 'Corticotropin', 'Hypothyroidism', 'Adrenocorticotropic agents may have enhanced effects in patients with hypothyroidism.  Dosage adjustments may be necessary in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5532, 0, 'Corticotropin', 'Myasthenia Gravis', 'While corticotropin has been used effectively in severe, refractory myasthenia gravis to increase muscle strength, it should nevertheless be administered with extreme caution in such setting.  Patients must be treated in an intensive care unit and receive respiratory support, since muscle strength will markedly decrease initially.  Improvement usually occurs several days after the first or second course of treatment.  Similar responses might be expected of other adrenocorticotropic agents, although their use in myasthenia gravis has not been studied extensively.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5533, 0, 'Corticotropin', 'Muscular Diseases', 'Toxic myopathy may occur with the prolonged use of adrenocorticotropic agents, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadraparesis.  Elevations of creatine kinase may also occur, albeit infrequently.  After withdrawal of ACTH therapy, recovery may be slow and incomplete.  Therapy with adrenocorticotropic agents should be administered cautiously in patients with preexisting myopathy or myoneural disorders, since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal or no changes of myopathy on EMG, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of adrenocorticotropic therapy should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5534, 0, 'Corticotropin', 'Thromboembolism', 'Adrenocorticotropic agents may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  These agents should be used cautiously in patients with thrombotic or thromboembolic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5535, 0, 'Conjugated estrogens', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5536, 0, 'Conjugated estrogens', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5537, 0, 'Conjugated estrogens', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5538, 0, 'Conjugated estrogens', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5539, 0, 'Conjugated estrogens', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5540, 0, 'Conjugated estrogens', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5541, 0, 'Conjugated estrogens', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5542, 0, 'Conjugated estrogens', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5543, 0, 'Conjugated estrogens', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5544, 0, 'Conjugated estrogens', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5545, 0, 'Conjugated estrogens', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5546, 0, 'Conjugated estrogens', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5547, 0, 'Conjugated estrogens', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5548, 0, 'Conjugated estrogens', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5549, 0, 'Conjugated estrogens', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5550, 0, 'Conjugated estrogens', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5551, 0, 'Coenzyme M', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5552, 0, 'Coenzyme M', 'Autoimmune Diseases', 'Mesna is a thiol (SH) compound.  Hypersensitivity reactions including anaphylaxis have occurred in patients with autoimmune disorders, the majority of whom received high dosages of mesna orally.  Therapy with mesna should be administered cautiously in patients with autoimmune disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5553, 0, 'Cromoglicic acid', 'Liver Diseases', 'Systemically absorbed cromolyn is eliminated almost equally by renal and biliary routes.  Although less than 1% of an orally ingested dose and approximately 8% of an orally inhaled dose is systemically available, the manufacturers recommend that a dosage reduction be considered in patients with impaired renal or hepatic function.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5554, 0, 'Collagenase clostridium histolyticum', 'Blood Coagulation Disorders', 'Collagenase clostridium histolyticum for injection should be avoided in patients with coagulation disorders, including those receiving concomitant anticoagulant medications, other than low-dose aspirin within seven days prior to therapy administration.  Care should be exercised if collagenase clostridium histolyticum for injection is used in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5555, 0, 'Crizotinib', 'Long QT Syndrome', 'The use of crizotinib can cause QTc prolongation.  It is recommended to avoid the use of this agent in patients with congenital long QT syndrome.  Use with caution when using this drug in patients with a history or predisposition to QTc prolongation.  Withhold in patients who develop QTc greater than 500 ms on at least 2 separate ECGs until recovery to a QTc less than or equal to 480 ms and resume drug treatment at a reduced dose.  Permanently discontinue in patients who develop QTc greater than 500 ms, or greater than or equal to 60 ms change from baseline with torsade de pointes, polymorphic ventricular tachycardia, or signs of serious arrhythmia.  Consider obtaining ECGs and electrolytes as close as possible prior to the first dose and periodic monitoring in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, history or predisposition for QTc prolongation, and taking medications that prolong the QT interval.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5556, 0, 'Crizotinib', 'Bradycardia', 'Crizotinib can cause symptomatic bradycardia.  It is recommended to monitor heart rate and blood pressure regularly.  It might be necessary to withhold crizotinib in cases of symptomatic bradycardia that is not life-threatening until recovery occurs and then resume treatment at an appropriate dose.  Permanently discontinue therapy for life-threatening bradycardia due to crizotinib treatment; however, if associated with concomitant medications known to cause bradycardia or hypotension, hold crizotinib until recovery and if concomitant medications can be adjusted or discontinued, restart treatment with crizotinib at 250 mg once daily with frequent monitoring.  Close monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5557, 0, 'Crizotinib', 'Peptic Ulcer Perforation', 'The use of crizotinib can cause gastrointestinal (GI) perforations.  This drug should be used with caution in patients at risk for GI perforation (e.g., history of diverticulitis, metastases to the gastrointestinal tract, concomitant use of medicinal products with a recognized risk of gastrointestinal perforation).  It is recommended to discontinue treatment in patients who develop GI perforation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5558, 0, 'Crizotinib', 'Hepatic Insufficiency', 'Crizotinib is extensively metabolized in the liver, and hepatic impairment is likely to increase plasma crizotinib concentrations.  Cases of drug-induced hepatotoxicity with fatal outcomes have been reported with the use of crizotinib.  It is recommended to monitor liver function tests, regularly as clinically indicated, with more frequent repeat testing for increased liver transaminases, alkaline phosphatase, or total bilirubin in patients who develop transaminase elevations and to temporarily suspend, reduce the dose, or permanently discontinue therapy as per recommended by the manufacturer.  Caution is recommended in patients with hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5559, 0, 'Crizotinib', 'Kidney Diseases', 'Based on a population pharmacokinetic analysis of crizotinib no starting dose adjustment is needed for patients with mild or moderate renal impairment.  Care should be exercised when using this agent in patients with severe renal impairment as the exposure to crizotinib is increased in these patients.  It is recommended to administer crizotinib at a dose of 250 mg taken orally once daily in patients with severe renal impairment not requiring dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5560, 0, 'Crizotinib', 'Vision Disorders', 'Cases of optic atrophy and optic nerve disorder leading to vision loss have been reported with the use of crizotinib.  It is recommended to perform an ophthalmological evaluation consisting of best corrected visual acuity, retinal photographs, visual fields, optical coherence tomography (OCT) and other evaluations as appropriate for new onset of severe visual loss.  Discontinue crizotinib in patients with new onset of severe visual loss.  There is insufficient information to characterize the risks of resumption of crizotinib in patients with a severe visual loss; a decision to resume treatment with crizotinib should consider the potential benefits to the patient.  Care should be exercised when prescribing crizotinib in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5561, 0, 'Crizotinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5562, 0, 'Conivaptan', 'Heart Failure', 'The amount of safety data on the use of conivaptan in patients with hypervolemic hyponatremia associated with heart failure is limited.  Conivaptan should only be used to raise sodium in such patients after consideration of other treatment options.  Caution is advised if using in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5563, 0, 'Conivaptan', 'Hepatic Insufficiency', 'The systemic exposure to unbound conivaptan doubled in subjects with moderate and severe hepatic impairment.  Caution is advised in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5564, 0, 'Conivaptan', 'Kidney Failure, Chronic', 'The use of conivaptan is not recommended in patients with severe renal impairment (CrCl < 30 mL/min), as there is an unlikely benefit.  There is also a high incidence of infusion site phlebitis, which can reduce vascular access sites.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5565, 0, 'Conivaptan', 'Liver Diseases', 'Osmotic demyelination syndrome is a risk associated with overly rapid correction of hyponatremia (> 12 mEq/L/24 hours).  This syndrome can result in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizure, coma or death.  Patients with advanced liver disease, alcoholism or severe malnutrition are at increased risk and require slower rates of correction.  Serum sodium concentration and neurological status should be monitored appropriately during treatment administration.  Vasopressin antagonists should be initiated and re- initiated in patients only in hospital settings were sodium levels can be monitored closely.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5566, 0, 'Copanlisib', 'Hepatic Insufficiency', 'Copanlisib is primarily metabolize by the liver.  Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild hepatic impairment.  The pharmacokinetics of copanlisib have not been evaluated in patients with moderate to severe hepatic impairment.  Close monitoring is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5567, 0, 'Copanlisib', 'Hyperglycemia', 'Hyperglycemia has occurred in patients treated with copanlisib.  Before starting copanlisib patients should achieve optimal blood glucose control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistent of hyperglycemia.  Diabetic patients should only be treated with this agent following adequate glucose control and should be monitored closely.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5568, 0, 'Copanlisib', 'Hypertension', 'Hypertension has occurred in patients treated with copanlisib.  Before starting copanlisib patients should achieve optimal blood pressure control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of hypertension.  It is recommended to monitor blood pressure before and after the infusion with copanlisib.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5569, 0, 'Copanlisib', 'Infections', 'Serious infections, including infections and non-infectious pneumonitis, have occurred in patients treated with copanlisib.  Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of jiroveci pneumonia infection.  It is recommended to monitor patients closely according to medical practice and for signs and symptoms of infection and to treat as medically appropriate.  The dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of symptoms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5570, 0, 'Copanlisib', 'Kidney Diseases', 'Copanlisib undergoes minimal renal elimination.  Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment.  The pharmacokinetic copanlisib has not been evaluated in patients with severe renal impairment or in those patients with end stage renal disease with or without dialysis.  Close monitoring is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5571, 0, 'Colistimethate', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5572, 0, 'Colistimethate', 'Kidney Diseases', 'Nephrotoxicity can occur with colistimethate and is probably dose-dependent; signs/symptoms of nephrotoxicity are reversible after discontinuation of therapy.  Overdosage can lead to renal dysfunction, muscle weakness, and apnea.  Respiratory arrest has been reported after IM administration of colistimethate.  Because renal dysfunction increases the risk of apnea and neuromuscular blockade after drug administration, it is important to follow recommended dosing guidelines.Colistimethate is eliminated primarily by renal excretion; caution is recommended when renal function may be impaired.  When renal dysfunction is confirmed, colistimethate may be used, but with particular caution and the dosage should be reduced in proportion to the extent of the impairment.  Administering amounts of colistimethate that exceed renal excretory capacity will result in high serum levels and can lead to further impairment of renal function, starting a cycle which, if not recognized, can cause acute renal insufficiency, renal shutdown, and further concentration of colistimethate to toxic levels in the body; at this point, interference of nerve transmission at neuromuscular junctions may occur and lead to muscle weakness and apnea.  Signs that indicate impairment of renal function is occurring include diminishing urine output, increasing BUN and serum creatinine, and decreased CrCl.  Therapy should be discontinued immediately if signs of renal dysfunction develop; however, if resumption of colistimethate is necessary, dosing should be adjusted accordingly after plasma drug levels have decreased.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5573, 0, 'Cyclobenzaprine', 'Cardiovascular Diseases', 'The manufacturers consider the use of cyclobenzaprine to be contraindicated in the acute recovery phase following myocardial infarction and in patients with hyperthyroidism, congestive heart failure, arrhythmias, heart block, and/or conduction disturbances.  Cyclobenzaprine is structurally related to the tricyclic antidepressants, which have been reported to cause tachycardia, arrhythmias, heart block, hypertension, hypotension (particularly orthostatic hypotension), thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with cyclobenzaprine should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease or a predisposition to hypotension, particularly if the intended dosage exceeds those normally used for musculoskeletal conditions.  Tachycardia, arrhythmia, palpitation, and hypotension have been reported with the use of cyclobenzaprine in less than 1% of patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5574, 0, 'Cyclobenzaprine', 'Anticholinergic Syndrome', 'Cyclobenzaprine has anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with cyclobenzaprine should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Glaucoma should be treated and under control prior to initiation of cyclobenzaprine therapy, and intraocular pressure monitored during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5575, 0, 'Cyproheptadine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5576, 0, 'Cyproheptadine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5577, 0, 'Cyproheptadine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5578, 0, 'Cyproheptadine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5579, 0, 'Cycloserine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5580, 0, 'Cycloserine', 'Central Nervous System Diseases', 'The use of cycloserine is contraindicated in patients with seizure disorders, depression, severe anxiety, dementia, psychoses, and alcoholism.  Cycloserine is associated with a high incidence of dose-related central nervous system (CNS) toxicities, including confusion, disorientation, aggression, anxiety, psychoses, depression with suicidal tendencies, paresis, seizures, and coma.  CNS effects may be more likely to occur with dosages greater than 500 mg/day, in chronic alcoholics, and during coadministration with ethionamide or isoniazid.  Toxicity correlates with blood levels exceeding 30 mcg/mL.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5581, 0, 'Cycloserine', 'Kidney Diseases', 'The use of cycloserine is contraindicated in patients with severe renal impairment.  Cycloserine is associated with a high incidence of neurotoxicities, which correlates with blood levels exceeding 30 mcg/mL.  Since cycloserine is primarily eliminated by the kidney, patients with renal impairment may be more likely to experience toxicity due to inadequate drug clearance.  Patients with reduced renal function should be monitored closely during therapy with cycloserine.  Blood levels should be drawn weekly, and dosage adjusted accordingly.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5582, 0, 'Cyclophosphamide', 'Bone Marrow Failure Disorders', 'The use of cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock.  Close monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.  Cyclophosphamide should not be administered to patients with neutrophils <1,500/mm3 and platelets < 50,000/mm3.  Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5583, 0, 'Cyclophosphamide', 'Urethral Obstruction', 'The use of cyclophosphamide is contraindicated in patients with any urinary outflow obstruction.  Before treatment initiation, urinary obstruction should be excluded or corrected.  Hemorrhagic cystitis, pyelitis, and hematuria have been reported during cyclophosphamide therapy.  Adequate hydration and use of a prophylactic agent such as mesna prior to each course of cyclophosphamide therapy reduces bladder irritation and hematuria.  Therapy with cyclophosphamide should be administered cautiously in patients with or predisposed to cystitis, including patients with active urinary infections.  Treatment should be discontinued if there is sign of urotoxicity as hemorrhagic cystitis, bladder ulceration, necrosis, fibrosis, contractures, etc.  Urinary sediment should be checked regularly for presence or erythrocytes and other signs of toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5584, 0, 'Cyclophosphamide', 'Cardiotoxicity', 'Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.  Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.  The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.  These patients should be closely monitored.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5585, 0, 'Cyclophosphamide', 'Liver Diseases', 'Cyclophosphamide is metabolized by the liver to a biologically active form.  Metabolic activation and therapeutic activity may be altered in patients with hepatic impairment.  Additionally, Veno-occlusive liver disease (VOD) sometimes with fatal outcome has been reported in patients receiving cyclophosphamide- containing regimens.  VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.  Preexisting disturbances of hepatic function seems to also be a risk factor.  Therapy with cyclophosphamide should be administered cautiously in patients with compromised hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5586, 0, 'Cyclophosphamide', 'Lung Diseases', 'Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide.  Pneumonitis may develop years after treatment with cyclophosphamide.  Patients should be monitored for signs and symptoms of pulmonary toxicity.  Caution is advised in patients with preexisting pulmonary impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5587, 0, 'Cyclophosphamide', 'Kidney Diseases', 'In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity.  Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.  Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction.  Clinical monitoring of renal function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5588, 0, 'Cyanocobalamin', 'Hypokalemia', 'Hypokalemia (resulting in death) has occurred during vitamin B12 therapy as a result of increased red blood cell requirements during hematopoiesis.  Clinical monitoring and correction of potassium levels prior to and during vitamin B12 therapy is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5589, 0, 'Cyanocobalamin', 'Optic Atrophy, Hereditary, Leber', 'The use of cyanocobalamin is contraindicated in patients with Leber''s disease (hereditary optic nerve atrophy).  Cyanocobalamin has induced severe and rapid optic nerve atrophy in patient''s with early Leber''s disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5590, 0, 'Cyanocobalamin', 'Malabsorption Syndromes', 'Absorption of vitamin B12 is decreased in malabsorption syndromes and in pernicious anemia without coadministration of intrinsic factor (IF).  Cyanocobalamin is rapidly absorbed following IM or subcutaneous injections.  Hydroxocobalamin (cyanocobalamin analog) functions the same a cyanocobalamin, but has induced antibody formation to the hydroxocobalamin-transcobalamin II complex.  The use of cyanocobalamin may be preferred in patients with these conditions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5591, 0, 'Cyanocobalamin', 'Kidney Diseases', 'Cyanocobalamin products contain aluminum that may be toxic and may reach toxic levels with prolonged parenteral administration if kidney function is impaired.  Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and other solutions which also contain aluminum.  Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum greater than 4-5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.  Caution and monitoring are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5592, 0, 'Cytarabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5593, 0, 'Cytarabine', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5594, 0, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5595, 0, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5596, 0, 'Aliskiren', 'Diabetes Mellitus', 'The use of aliskiren is contraindicated in patients with diabetes who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), as there is an increased risk of renal impairment, hyperkalemia, and hypotension.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5597, 0, 'Aliskiren', 'Hypotension', 'Symptomatic hypotension may occur after treatment initiation with aliskiren in patients with marked volume depletion, salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system.  It is recommended to correct the volume or salt depletion before administering aliskiren.  Close monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5598, 0, 'Aliskiren', 'Kidney Diseases', 'Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure.  Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure.  Treatment should be discontinued in any patients who develop clinically significant decrease in renal function.  Patients with renal impairment should be observed closely.  The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5599, 0, 'Dacarbazine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5600, 0, 'Dacarbazine', 'Liver Diseases', 'The pharmacokinetic disposition of dacarbazine may be altered in patients with hepatic impairment.  Hepatotoxicity, including hepatic vein thrombosis and hepatocellular necrosis, have been reported.  Patients should be instructed to immediately report any sign or symptoms of liver dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with dacarbazine should be administered cautiously in patients with or predisposed to compromised hepatic function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5601, 0, 'Dacarbazine', 'Bone Marrow Failure Disorders', 'Dacarbazine is myelosuppressive, primarily affecting  leukocytes and thrombocytes, although anemia occasionally occurs.  Deaths due to myelosuppression have been reported.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Therapy with dacarbazine should be withheld or extreme caution exercised when administered in patients whose bone marrow reserve may be severely depressed.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5602, 0, 'Dacarbazine', 'Kidney Diseases', 'Dacarbazine is partially eliminated by the kidney via renal tubular secretion.  Approximately 40% of dacarbazine is eliminated unchanged in the urine.  The half-life of dacarbazine may be increased in patients with renal impairment.  Rare reports of unspecified, severe renal toxicity has been noted.  Therapy with dacarbazine should be administered cautiously to patients with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5603, 0, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5604, 0, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5605, 0, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5606, 0, 'Dabrafenib', 'Cardiomyopathies', 'Cardiomyopathy/reduction in left ventricular ejection fraction (LVEF) has been reported with the use of dabrafenib.  Exercise caution when using this drug in patients at risk of conditions that could impair left ventricular function.  It is recommended to assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of therapy, 1 month after, and then at 2- to 3-month intervals while on treatment.  Withhold therapy for symptomatic cardiomyopathy or asymptomatic LV dysfunction of greater than 20% from baseline that is below institutional lower level of normal.  Resume therapy at the same dose level upon recovery of cardiac function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5607, 0, 'Dabrafenib', 'Diabetes Mellitus', 'The use of dabrafenib may cause hyperglycemia in patients with a history of diabetes.  Care should be exercised when using this drug in diabetic patients.  It is recommended to monitor serum glucose levels at the start of therapy and as clinically indicated.  Initiate or optimize anti-hyperglycemic medications as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5608, 0, 'Dabrafenib', 'Fever', 'Serious febrile reactions and fever of any severity complicated by rigors or chills, hypotension, dehydration, and/or renal failure have been observed with the use of dabrafenib.  The incidence and severity of pyrexia are increased when this drug is administered in combination with trametinib.  Patients with serious non-infectious febrile events responded well to dose interruption and/or dose reduction and supportive care.  It is recommended to withhold therapy for fever of 38.5 degrees Celsius (101.3 degrees Fahrenheit) or higher, for any serious febrile reaction, or fever associated with complications; evaluate for infection.  Consider the administration of antipyretics to resolve fever, and as secondary prophylaxis when resuming therapy for patients with prior episode of severe febrile reaction or fever associated with complications.  For instances in which antipyretics are insufficient, consider administering corticosteroids.  Upon resolution of pyrexia, dose reduction and/or permanent therapy discontinuation may be required.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5609, 0, 'Dabrafenib', 'Glucosephosphate Dehydrogenase Deficiency', 'Dabrafenib contains a sulfonamide moiety.  Care should be exercised when using this drug in patients with glucose-6-phosphate dehydrogenase (G6PD) as it may increase the risk of hemolytic anemia.  It is recommended to monitor patients with G6PD deficiency for signs of hemolytic anemia during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5610, 0, 'Dabrafenib', 'Hemorrhage', 'The use of dabrafenib may increase the change of hemorrhagic events.  Use care when using this drug in patients at risk of bleeding.  It is recommended to permanently discontinue treatment for all Grade 4 hemorrhagic events and for any Grade 3 hemorrhagic events that do not improve.  Withhold therapy for Grade 3 hemorrhagic events; if improved, resume at the next lower dose level.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5611, 0, 'Dabrafenib', 'Toxic Optic Neuropathy', 'The use of dabrafenib may cause uveitis, including iritis and iridocyclitis.  Care should be exercised when using this agent in patients at risk of ocular toxicities.  During therapy, it is recommended to routinely monitor patients for visual signs and symptoms of uveitis, such as a change in vision, photophobia, and eye pain.  Upon examination, if iritis is diagnosed administer ocular therapy, and continue this drug without a dose modification.  For severe uveitis or iridocyclitis, interrupt therapy and treat as clinically indicated and permanently discontinue treatment for persistent Grade 2 or greater uveitis of 6 weeks or more.  No dose modifications are required if treatment effectively controls ocular inflammation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5612, 0, 'Dabrafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5613, 0, 'Dalbavancin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5614, 0, 'Dalbavancin', 'Liver Diseases', 'Therapy with dalbavancin should be administered cautiously in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as no data are available to determine the appropriate dosing in these patients.  No dosage adjustment is recommended for patients with mild liver dysfunction (Child-Pugh A).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5615, 0, 'Dalbavancin', 'Kidney Diseases', 'The recommended regimen for dalbavancin in patients with CrCl less than 30 mL/min who are not receiving regularly scheduled hemodialysis is 1125 mg as a single dose OR 750 mg once, followed by 375 mg one week later.  No dosage adjustment is necessary for patients with CrCl greater than 30 mL/min or for patients receiving regularly scheduled hemodialysis; dalbavancin may be administered without regard to the timing of hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5616, 0, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5617, 0, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5618, 0, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5619, 0, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5620, 0, 'Dalfampridine', 'Kidney Diseases', 'Dalfampridine is contraindicated in patients with moderate or severe renal impairment (CrCl<=50 mL/min).  Dalfampridine is eliminated through the kidneys primarily as unchanged drug and its clearance is decreased in patients with renal impairment and is significantly correlated with creatinine clearance.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5621, 0, 'Dalfampridine', 'Seizures', 'Dalfampridine is contraindicated in patients with a history of seizures.  Dalfampridine can cause seizures and it is recommended to permanently discontinue treatment in patients who have a seizure while on treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5622, 0, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5623, 0, 'Dacomitinib', 'Kidney Diseases', 'The recommended dose of dacomitinib has not been established for patients with severe renal impairment (CrCl <30 mL/min).  Caution is advised if used in these patients.  No dose adjustment is recommended for patients with mild or moderate renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5624, 0, 'Dacomitinib', 'Liver Failure', 'The recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (total bilirubin > 3 to 10  ULN and any AST).  Caution is advised if used in these patients.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5625, 0, 'Dactinomycin', 'Infections', 'The use of dactinomycin is contraindicated in patients with known or suspected varicella-zoster or herpes zoster infections.  A severe, generalized, potentially fatal disease has been reported with dactinomycin use during or about the time of such infections.  In addition, dactinomycin can induce myelosuppression, particularly when used with X-ray therapy.  Therefore, dactinomycin therapy should be withheld, or given cautiously, in patients with an infection, depending on the severity.  Close clinical monitoring of hematopoietic function is recommended whenever the drug is administered.  If white blood cell and/or platelet counts are markedly decreased, therapy should be withheld to allow marrow recovery, which often takes up to three weeks.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5626, 0, 'Dactinomycin', 'Liver Failure', 'Hepatotoxicity can occur with the use of dactinomycin for injection.  Monitor AST, ALT, alkaline phosphatase, and bilirubin prior to and during dactinomycin therapy.  Caution is advised if used in patients with preexisting liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5627, 0, 'Dactinomycin', 'Bone Marrow Failure Disorders', 'Severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia and anemia, can occur with dactinomycin.  If either the white blood cell or platelet count is markedly decreased, therapy with dactinomycin should be withheld or dose should be reduced to allow recovery.  Therapy with dactinomycin should be administered cautiously in patients with myelosuppression.  Close clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5628, 0, 'Dactinomycin', 'Kidney Diseases', 'Abnormalities of renal function can occur with dactinomycin for injection.  Monitor creatinine and electrolytes frequently during dactinomycin therapy.  Caution is advised if used in patients with preexisting renal disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5629, 0, 'Danaparoid', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5630, 0, 'Danaparoid', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5631, 0, 'Danaparoid', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5632, 0, 'Danaparoid', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5633, 0, 'Danaparoid', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5634, 0, 'Danaparoid', 'Hypertension', 'Anticoagulants should be used with extreme caution in patients at increased risk for hemorrhage, including those patients with severe hypertension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5635, 0, 'Danaparoid', 'Kidney Diseases', 'Anticoagulants should be given with extreme caution to patients with severe kidney dysfunction.  Altered coagulation may increase the risk of bleeding in these patients.  If an anticoagulant is administered, these patients should be monitored closely for signs of bleeding.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5636, 0, 'Darunavir', 'Liver Diseases', 'Drug-induced hepatitis has been reported with the use of darunavir/ritonavir.  Patients with underlying liver disease including chronic active hepatitis B or C viral infections have an increased risk for liver function abnormalities.  Therapy with darunavir should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  The combination of darunavir/ritonavir is not recommended for use in patients with severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5637, 0, 'Darunavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5638, 0, 'Darunavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5639, 0, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5640, 0, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5641, 0, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5642, 0, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5643, 0, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5644, 0, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5645, 0, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5646, 0, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5647, 0, 'Dalteparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5648, 0, 'Dalteparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5649, 0, 'Dalteparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5650, 0, 'Dalteparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5651, 0, 'Dalteparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5652, 0, 'Dalteparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5653, 0, 'Dalteparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5654, 0, 'Dalteparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5655, 0, 'Dalteparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5656, 0, 'Dalteparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5657, 0, 'Darolutamide', 'Hepatic Insufficiency', 'Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose).  No dose reduction is needed for patients with mild hepatic impairment.  The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5658, 0, 'Darolutamide', 'Kidney Diseases', 'Patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2) who are not receiving hemodialysis have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose).  No dose reduction is needed for patients with mild or moderate renal impairment.  The effect of end stage renal disease (eGFR <15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5659, 0, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5660, 0, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5661, 0, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5662, 0, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5663, 0, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5664, 0, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5665, 0, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5666, 0, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5667, 0, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5668, 0, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5669, 0, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5670, 0, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5671, 0, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5672, 0, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5673, 0, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5674, 0, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5675, 0, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5676, 0, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5677, 0, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5678, 0, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5679, 0, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5680, 0, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5681, 0, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5682, 0, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5683, 0, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5684, 0, 'Daunorubicin', 'Heart Failure', 'Daunorubicin can cause myocardial toxicity leading to congestive heart failure.  Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure.  The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2.  An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5685, 0, 'Daunorubicin', 'Infections', 'Daunorubicin can induce severe myelosuppression at therapeutic doses.  The use of daunorubicin may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5686, 0, 'Daunorubicin', 'Bone Marrow Failure Disorders', 'Daunorubicin hydrochloride is a potent bone marrow suppressant.  Suppression will occur in all patients given a therapeutic dose of the drug.  Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk.  Persistent, severe myelosuppression may result in superinfection or hemorrhage.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5687, 0, 'Daunorubicin', 'Liver Diseases', 'Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes.  Further metabolism via reduction and conjugation has been demonstrated.  Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function.  Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5688, 0, 'Daunorubicin', 'Kidney Diseases', 'Approximately 25% of daunorubicin is eliminated in an active form in the urine.  Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin.  Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function.  Clinical evaluation of renal function prior to each course of treatment is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5689, 0, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5690, 0, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5691, 0, 'Deferoxamine', 'Kidney Diseases', 'The use of deferoxamine is contraindicated in patients with severe renal impairment or anuria.  Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5692, 0, 'Deferoxamine', 'Auditory Diseases, Central', 'Neurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with hearing impairment.  Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5693, 0, 'Deferoxamine', 'Hepatic Insufficiency', 'No studies of deferoxamine have been performed in patients with hepatic impairment.  Caution is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5694, 0, 'Deferoxamine', 'Toxic Optic Neuropathy', 'Deferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision.  Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects.  Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy.  Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5695, 0, 'Deferoxamine', 'Respiratory Distress Syndrome', 'Acute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine.  Caution is recommended when using deferoxamine in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5696, 0, 'Decitabine', 'Liver Failure', 'There are no data on the use of decitabine in patients with hepatic dysfunction.  Decitabine should be used with caution in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5697, 0, 'Decitabine', 'Hematologic Diseases', 'Treatment with decitabine is associated with neutropenia and thrombocytopenia.  It is recommended to consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with myelodysplastic syndromes (MDS).  Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, before each dosing cycle.  After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted according to manufacturer recommendations.  Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS.  Closely monitor patients at risk for hematological toxicities.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5698, 0, 'Decitabine', 'Kidney Diseases', 'There are no data on the use of decitabine in patients with renal dysfunction.  Decitabine should be used with caution in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5699, 0, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5700, 0, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5701, 0, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5702, 0, 'Deferasirox', 'Kidney Diseases', 'The use of deferasirox is contraindicated in patients with serum creatinine greater than two times the age-appropriate upper limit of normal or creatinine clearance less than 40 mL/min.  The starting dose of deferasirox should be reduced by 50% in patients with creatine clearance 40 to 60 mL/min.  It is recommended to measure serum creatine and calculate clearance in duplicate prior to initiating treatment in all patients and monitor renal function at least monthly or more frequently as clinically appropriate.  Consider dose reduction, interruption, or discontinuation of deferasirox based on increases in serum creatinine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5703, 0, 'Deferasirox', 'Auditory Diseases, Central', 'Auditory disturbances (high-frequency hearing loss, decreased hearing), and ocular disturbances (lens opacities, cataracts, elevations in intraocular pressure, and retinal disorders) have been reported in patients using deferasirox.  It is recommended to perform auditory and ophthalmic testing (including slit lamp examinations and dilated fundoscopy) before starting therapy with deferasirox and thereafter as clinically indicated.  If disturbances are noted, consider dose reduction or interruption if appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5704, 0, 'Deferasirox', 'Gastrointestinal Diseases', 'Gastrointestinal hemorrhage, ulcerations, perforations, including deaths have been documented in patients using deferasirox, especially in elderly patients who had advanced hematologic malignancies and/or low platelet counts.  The risk of gastrointestinal hemorrhage may be increased when administering deferasirox in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants.  It is recommended to monitor patients and discontinue therapy for suspected GI ulceration or hemorrhage.  Care is recommended when using this agent in patients at risk of GI complications.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5705, 0, 'Deferiprone', 'Agranulocytosis', 'Fatal agranulocytosis and neutropenia can occur with the use of deferiprone.  It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate.  Manage agranulocytosis/neutropenia prior to initiating treatment.  Therapy should be interrupted if neutropenia develops or if an infection develops.  Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5706, 0, 'Deferiprone', 'Hepatic Insufficiency', 'A clinical study to evaluate the effect of impaired hepatic function on the pharmacokinetics of deferiprone showed that mild and moderate hepatic impairment do not influence the pharmacokinetics of deferiprone and major metabolite, deferiprone 3-O-glucuronide.  Based on the results, no dose adjustment is required in patients with mildly or moderately hepatic impairment.  Caution is recommended when using this agent in patients with severe hepatic impairment as the pharmacokinetics of deferiprone and deferiprone have not been evaluated.  It is recommended to monitor serum transaminase values monthly during therapy and to consider interruption if there is a persistent increase in serum transaminase levels.  Close monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5707, 0, 'Almotriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5708, 0, 'Almotriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5709, 0, 'Almotriptan', 'Liver Diseases', 'Almotriptan is partially metabolized by the liver.  The pharmacokinetics of almotriptan have not been assessed in patients with hepatic impairment.  Based on the known mechanisms of clearance of almotriptan, the maximum decrease in clearance expected due to hepatic impairment would be 60%.  The manufacturer recommends that a starting dose of 6.25 mg be used in patients with significantly impaired hepatic function, and that the maximum dosage not exceed 12.5 mg per 24-hour period.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5710, 0, 'Almotriptan', 'Kidney Diseases', 'Approximately 40% of an administered dose of almotriptan is excreted unchanged in the urine.  Following oral administration in patients with renal impairment, the clearance of almotriptan was approximately 65% lower in patients with severe impairment (CrCl = 10 to 30 mL/min) and 40% lower in patients with moderate impairment (CrCl = 31 to 71 mL/min) compared to healthy controls.  Peak plasma concentrations of almotriptan increased by approximately 80% in these patients.  The manufacturer recommends that a starting dose of 6.25 mg be used in patients with significantly impaired renal function, and that the maximum dosage not exceed 12.5 mg per 24-hour period.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5711, 0, 'Deflazacort', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5712, 0, 'Deflazacort', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5713, 0, 'Deflazacort', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5714, 0, 'Deflazacort', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5715, 0, 'Deflazacort', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5716, 0, 'Deflazacort', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5717, 0, 'Deflazacort', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5718, 0, 'Deflazacort', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5719, 0, 'Deflazacort', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5720, 0, 'Deflazacort', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5721, 0, 'Deflazacort', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5722, 0, 'Deflazacort', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5723, 0, 'Deflazacort', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5724, 0, 'Deflazacort', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5725, 0, 'Deflazacort', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5726, 0, 'Deflazacort', 'Hepatic Insufficiency', 'No dose adjustment of deflazacort is required for patients with mild or moderate liver dysfunction.  Care is recommended when using deflazacort in patients with severe liver dysfunction; a dosing recommendation cannot be provided as there is no clinical experience in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5727, 0, 'Deflazacort', 'Infections', 'Corticosteroids (including deflazacort) suppress the immune system and increase the risk of infection with any pathogen (including viral, bacterial, fungal, protozoan, or helminthic).  Corticosteroids mask some signs of infection, decrease resistance to new infections, exacerbate existing infections, and increase the risk of disseminated infections; these infections can be severe and sometimes fatal.  The degree to which the dose, route, and duration of corticosteroid therapy correlates with the specific risks of infection is not well described; however, the rate of occurrence of infectious complications increases with increasing corticosteroid doses.  Patients should be monitored for infection and dose reduction or discontinuation of corticosteroids should be considered as needed.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5728, 0, 'Delavirdine', 'Achlorhydria', 'Patients with achlorhydria should take delavirdine with an acidic beverage such as orange or cranberry juice, presumably to improve absorption.  Although the effects of acidic beverages on delavirdine absorption have not been studied, delavirdine is known to be poorly soluble when pH is greater than 3.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5729, 0, 'Delavirdine', 'Liver Diseases', 'Delavirdine is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for toxicities and adverse effects from delavirdine due to decreased drug clearance.  Therapy with delavirdine should be administered cautiously in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5730, 0, 'Delafloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5731, 0, 'Delafloxacin', 'Kidney Diseases', 'The use of delafloxacin is not recommended in patients with End Stage Renal Disease (ESRD).  In patients with severe renal impairment or ESRD, accumulation of the intravenous vehicle, sulfobutylether-beta-cyclodextrin (SBECD) occurs.  No dosage adjustment is necessary in patients with mild or moderate renal impairment.  The dose of delafloxacin intravenous IV infusion in patients with severe renal impairment should be decreased to 200 mg intravenously every 12 hours; the oral dose in patients with severe renal impairment is 450 mg orally every 12 hours.  It is recommended to closely monitor serum creatinine in patients with severe renal impairment receiving intravenous delafloxacin and if serum creatinine level increases, consideration should be given to changing to the oral form of delafloxacin.  If eGFR decreases to <15 mL/min/1.73 m2, the drug should be discontinued.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5732, 0, 'Delafloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5733, 0, 'Delafloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5734, 0, 'Delafloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5735, 0, 'Delafloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5736, 0, 'Delafloxacin', 'Aortic Aneurysm', 'The use of certain fluoroquinolones may increase the risk of aortic aneurysm and dissection.  It is recommended to reserve the use of delafloxacin only when there are no alternative antibacterial treatments available in patients with a known aortic aneurysm or patients who are at higher risk for aortic aneurysms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5737, 0, 'Delafloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5738, 0, 'Delafloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5739, 0, 'Abatacept', 'Pulmonary Disease, Chronic Obstructive', 'In studies, patients with chronic obstructive pulmonary disease (COPD) treated with abatacept for rheumatoid arthritis developed adverse events (including COPD exacerbations, cough, rhonchi, dyspnea) more frequently than those treated with placebo.  Abatacept should be used with caution in patients with COPD and such patients should be monitored for worsening of their respiratory status.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5740, 0, 'Abatacept', 'Diabetes Mellitus', 'Parenteral drug products containing maltose can interfere with readings from blood glucose monitors that use test strips with glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ).  The GDH-PQQ-based glucose monitoring systems may react with the maltose in abatacept for IV administration, resulting in falsely elevated blood glucose readings on the day of abatacept infusion.  When receiving IV abatacept, patients that require blood glucose monitoring should be advised to consider methods that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose hexokinase test methods.Because abatacept for subcutaneous administration does not contain maltose, patients do not need to alter their glucose monitoring.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5741, 0, 'Abatacept', 'Hepatitis B', 'Because antirheumatic therapies have been associated with hepatitis B reactivation, patients should be screened for viral hepatitis in accordance with published guidelines before starting therapy with abatacept.  Patients screening positive for hepatitis were excluded from clinical studies with abatacept.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5742, 0, 'Abatacept', 'Infections', 'Serious infections (including sepsis, pneumonia) have been reported in patients receiving abatacept.  Caution and close monitoring are recommended when considering the use of abatacept in patients with history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of abatacept should be discontinued if a patient develops a serious infection.Posttransplant lymphoproliferative disorder (PTLD) and cytomegalovirus (CMV) invasive disease occurred in patients who received abatacept for acute graft versus host disease (aGVHD) prophylaxis during unrelated hematopoietic stem cell transplantation (HSCT); the PTLD events were associated with Epstein-Barr virus (EBV) infection.  Patients should be monitored for EBV reactivation according to institutional practices; prophylaxis for EBV infection should be provided for 6 months posttransplantation to prevent EBV-associated PTLD.  Patients should be monitored for CMV infection/reactivation for 6 months posttransplant regardless of pretransplant CMV serology results for donor and recipient; prophylaxis for CMV infection/reactivation should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5743, 0, 'Abatacept', 'Tuberculosis', 'Prior to initiating abatacept, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with abatacept.  Caution should be taken when prescribing abatacept to these patients as this agent has not been studied in patients with a positive tuberculosis screen, and the safety of abatacept in patients with latent tuberculosis infection is unknown.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5744, 0, 'Denosumab', 'Hypocalcemia', 'Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab.  Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis.  Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection.  It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5745, 0, 'Denosumab', 'IMMUNE SUPPRESSION', 'Denosumab should be used with caution in patients with impaired immune systems or taking concomitant immunosuppressant agents as they may be at increased risk for serious infections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5746, 0, 'Demeclocycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5747, 0, 'Demeclocycline', 'Diabetes Insipidus, Nephrogenic', 'The use of demeclocycline has been associated with a dose-dependent, reversible, nephrogenic diabetes insipidus syndrome in some patients receiving long-term therapy.  Symptoms of diabetes insipidus include polyuria, polydipsia, and weakness.  Therapy with demeclocycline should be administered cautiously in patients with preexisting nephrogenic diabetes insipidus.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5748, 0, 'Demeclocycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5749, 0, 'Demeclocycline', 'Kidney Diseases', 'Tetracyclines (except doxycycline) are eliminated by the kidney to various extent.  Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance.  Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment.  Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5750, 0, 'Demeclocycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5751, 0, 'Deoxycholic acid', 'Deglutition Disorders', 'The use of deoxycholic acid might cause dysphagia.  It is recommended to avoid the use of this agent in patients with a current or prior history of dysphagia as deoxycholic acid may exacerbate this condition.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5752, 0, 'Deoxycholic acid', 'Hemorrhage', 'The use of deoxycholic acid might cause injection site hematoma/bruising.  It is recommended to use deoxycholic acid with caution in patients with bleeding abnormalities and those who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5753, 0, 'Degarelix', 'Hepatic Insufficiency', 'Hepatic impairment can lower degarelix exposure.  It is recommended to monitor testosterone concentrations on a monthly basis in patients with hepatic impairment until medical castration is achieved.  Degarelix has not been studied in patients with severe hepatic impairment and caution is therefore warranted in this group of patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5754, 0, 'Degarelix', 'Kidney Diseases', 'Data on patients with moderate or severe renal impairment is limited and therefore degarelix should be used with caution in patients with CrCl < 50 mL/min.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5755, 0, 'Degarelix', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5756, 0, 'Desonide (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5757, 0, 'Desonide (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5758, 0, 'Desonide (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5759, 0, 'Desonide (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5760, 0, 'Desonide (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5761, 0, 'Dexmethylphenidate', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5762, 0, 'Dexmethylphenidate', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5763, 0, 'Dexmethylphenidate', 'Glaucoma', 'The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5764, 0, 'Dexmethylphenidate', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5765, 0, 'Dexmethylphenidate', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5766, 0, 'Dexmethylphenidate', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5767, 0, 'Dexmethylphenidate', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5768, 0, 'Dexmethylphenidate', 'Epilepsy', 'There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures.  The medication should be discontinued if seizures occur during its use.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5769, 0, 'Dexmethylphenidate', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5770, 0, 'Dexmethylphenidate', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5771, 0, 'Dexmethylphenidate', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5772, 0, 'Dexmethylphenidate', 'Hematologic Diseases', 'Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate.  However, a causal relationship has not been established.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5773, 0, 'Desmopressin', 'Kidney Diseases', 'The use of desmopressin is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5774, 0, 'Desmopressin', 'Water Intoxication', 'Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action.  Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects.  Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure.  Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma.  The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5775, 0, 'Desmopressin', 'Thromboembolism', 'Rare cases of thrombotic events (thrombosis, acute cerebrovascular thrombosis, and acute myocardial infarction) have been reported following desmopressin injection in patients predisposed to thrombus formation.  Although a causal relationship has not been established, therapy with desmopressin should be administered cautiously in patients with a current or past history of thrombotic or thromboembolic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5776, 0, 'Desmopressin', 'Vascular Diseases', 'The use of desmopressin, primarily in parenteral administration and/or in large doses, has been infrequently associated with changes in blood pressure, causing either slight elevations or transient decreases with a compensatory increase in heart rate.  Therapy with desmopressin, regardless of route of administration, should be administered cautiously in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5777, 0, 'Desoximetasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5778, 0, 'Desoximetasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5779, 0, 'Desoximetasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5780, 0, 'Desoximetasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5781, 0, 'Desoximetasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5782, 0, 'Alosetron', 'Gastrointestinal Diseases', 'Alosetron is contraindicated in patients with a history of severe bowel complications.  Patients with serious complications of constipation, including history of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; obstruction, ileus, impaction, toxic megacolon, secondary bowel ischemia, and impaired intestinal circulation should not use alosetron.  Care should be exercised when using this agent in patients at risk.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5783, 0, 'Alosetron', 'Hepatic Insufficiency', 'Alosetron is extensively metabolized by the liver.  The use of alosetron is contraindicated in patients with severe hepatic impairment and it should be used with caution in patients with mild or moderate hepatic impairment.  Close monitoring is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5784, 0, 'Alosetron', 'Coagulation Defect', 'The use of alosetron is contraindicated in patients with coagulation abnormalities such as thrombophlebitis, or hypercoagulable state.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5785, 0, 'Alosetron', 'Kidney Diseases', 'Renal impairment has no effect on the renal elimination of alosetron due to the minor contribution of this pathway to elimination.  Care should be exercised as the effect of renal impairment on metabolite pharmacokinetics and the effect of end-stage renal disease have not been assessed.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5786, 0, 'Dexmedetomidine', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5787, 0, 'Dexmedetomidine', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5788, 0, 'Dexmedetomidine', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5789, 0, 'Dexmedetomidine', 'Cardiomyopathies', 'The use of dexmedetomidine injection infusion decreases sympathetic nervous system activity and can cause hypotension, significant bradycardia and sinus arrest.  Caution should be exercised when administered to patients with advanced heart block, severe ventricular dysfunction or any significant cardiovascular dysfunction.  Hypotension or bradycardia can be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, chronic hypertension and in the elderly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5790, 0, 'Desloratadine', 'Asthma', 'Desloratadine products contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.  Caution is advised when using these products in people with asthma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5791, 0, 'Desloratadine', 'Liver Diseases', 'Dosing adjustment of desloratadine is recommended for patients with renal or hepatic impairment.  Dosing recommendations for children with liver or renal impairment cannot be made due to lack of data.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5792, 0, 'Desvenlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5793, 0, 'Desvenlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5794, 0, 'Desvenlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5795, 0, 'Desvenlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5796, 0, 'Desvenlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5797, 0, 'Desvenlafaxine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5798, 0, 'Desvenlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5799, 0, 'Desvenlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5800, 0, 'Alogliptin', 'Pancreatitis', 'There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors.  These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk.  Patients should be observed for signs and symptoms of pancreatitis during treatment.  If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5801, 0, 'Alogliptin', 'Liver Diseases', 'There have been postmarketing reports of hepatic failure (fatal and non-fatal) in patients taking alogliptin.  Treatment should be started with caution in patients with preexisting liver disease.  It is recommended to assess the liver function of the patient before starting therapy.  If liver test abnormalities worsen without explanation during treatment, therapy should be discontinued and the cause of the abnormalities should be studied.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5802, 0, 'Alogliptin', 'Kidney Diseases', 'It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors.  Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment.  Linagliptin will not require a dose adjustment per manufacturer''s information.  Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses.  However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5803, 0, 'Desirudin', 'Hemorrhage', 'The use of thrombin inhibitors is contraindicated in the presence of active major bleeding.  Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5804, 0, 'Deutetrabenazine', 'Depressive Disorder', 'The use of deutetrabenazine is contraindicated in patients with Huntington''s disease who are suicidal, or have untreated or uncontrolled depression.  Deutetrabenazine can increase the risk of depression and suicidal thoughts and behavior in these patients.  Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5805, 0, 'Deutetrabenazine', 'Liver Diseases', 'The use of deutetrabenazine is contraindicated in patients with hepatic impairment.  The effect of hepatic impairment on the pharmacokinetics of deutetrabenazine and its primary metabolites has not been studied; however, in a clinical study conducted with a closely related VMAT2 inhibitor, there was a large increase in exposure to this drug and its active metabolites in patients with hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5806, 0, 'Deutetrabenazine', 'Long QT Syndrome', 'The use of deutetrabenazine should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5807, 0, 'Deutetrabenazine', 'Neuroleptic Malignant Syndrome', 'Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission such as, deutetrabenazine.  Deutetrabenazine should be used with caution in patients presenting similar signs and symptoms of NMS.  Clinicians should be alerted to the signs and symptoms associated with NMS.  Recurrence of NMS has been reported with resumption of drug therapy.  If treatment with deutetrabenazine is needed after recovery from NMS, patients should be monitored for signs of recurrence.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5808, 0, 'Deutetrabenazine', 'Parkinson Disease', 'The use of vesicular monoamine transporter 2 (VMAT2) inhibitor, such as valbenazine and deutetrabenazine may cause parkinsonism in patients with tardive dyskinesia.  These agents should be used with caution in patients with parkinson disease or those presenting with parkinson-like symptoms such as, falls, gait disturbances, tremor, drooling and hypokinesia.  It is recommended to reduce the dose or to discontinue treatment in patients who develop clinically significant parkinson-like signs or symptoms while on treatment with these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5809, 0, 'Dexbrompheniramine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5810, 0, 'Dexbrompheniramine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5811, 0, 'Dexbrompheniramine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5812, 0, 'Dexbrompheniramine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5813, 0, 'Dextroamphetamine', 'Cardiovascular Diseases', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism.  Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure.  Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use.  In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities.  In general, amphetamines should not be used in patients with structural cardiac abnormalities.  If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5814, 0, 'Dextroamphetamine', 'Glaucoma', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  Like other sympathomimetic amines, amphetamines can induce transient mydriasis.  In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma.  If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5815, 0, 'Dextroamphetamine', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5816, 0, 'Dextroamphetamine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5817, 0, 'Dextroamphetamine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5818, 0, 'Dextroamphetamine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5819, 0, 'Dextroamphetamine', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5820, 0, 'Dextroamphetamine', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5821, 0, 'Dextroamphetamine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5822, 0, 'Dextroamphetamine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5823, 0, 'Dextroamphetamine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5824, 0, 'Dextroamphetamine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5825, 0, 'Dextroamphetamine', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5826, 0, 'Dexamethasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5827, 0, 'Dexamethasone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5828, 0, 'Dexamethasone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5829, 0, 'Dexamethasone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5830, 0, 'Dexamethasone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5831, 0, 'Dexamethasone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5832, 0, 'Dexamethasone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5833, 0, 'Dexamethasone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5834, 0, 'Dexamethasone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5835, 0, 'Dexamethasone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5836, 0, 'Dexamethasone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5837, 0, 'Dexamethasone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5838, 0, 'Dexamethasone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5839, 0, 'Dexamethasone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5840, 0, 'Dexamethasone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5841, 0, 'Dexamethasone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5842, 0, 'Dexamethasone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5843, 0, 'Dexamethasone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5844, 0, 'Dexamethasone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5845, 0, 'Dexamethasone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5846, 0, 'Dexamethasone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5847, 0, 'Dexamethasone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5848, 0, 'Dexlansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5849, 0, 'Dexlansoprazole', 'Liver Diseases', 'Dexlansoprazole is primarily metabolized by the liver.  No dosage adjustment is necessary for patients with mild hepatic impairment (Child Pugh Class A).  A dose of 30 mg should be considered for patients with moderate hepatic impairment (Child Pugh Class B).  No studies have been conducted in patients with severe hepatic impairment (Child Pugh Class C).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5850, 0, 'Dexlansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5851, 0, 'Dexlansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5852, 0, 'Desipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5853, 0, 'Desipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5854, 0, 'Desipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5855, 0, 'Desipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5856, 0, 'Desipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5857, 0, 'Desipramine', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5858, 0, 'Desipramine', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5859, 0, 'Desipramine', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5860, 0, 'Desipramine', 'Liver Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) are known to undergo metabolism in the liver.  Some of the metabolites, such as those of imipramine, clomipramine and desipramine, may be pharmacologically active.  Many of the metabolites are also excreted by the kidney.  There are very limited data concerning the use of TCAs in patients with renal and/or liver disease.  Therapy with TCAs should be administered cautiously in patients with significantly impaired renal or hepatic function.  Dosage adjustments may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5861, 0, 'Desipramine', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5862, 0, 'Desipramine', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5863, 0, 'Desipramine', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5864, 0, 'Desipramine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tricyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tricyclic antidepressants are not approved for use in treating bipolar depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5865, 0, 'Desipramine', 'Glaucoma', 'Tricyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.  Doxepin hydrochloride capsules are contraindicated in patients with glaucoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5866, 0, 'Desipramine', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5867, 0, 'Desipramine', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5868, 0, 'Desipramine', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5869, 0, 'Alpelisib', 'Skin Diseases', 'Severe cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Erythema Multiforme (EM) were reported in patients treated with alpelisib.  Do not initiate alpelisib treatment in patients with a history of SJS, EM, or Toxic Epidermal Necrolysis (TEN).  If signs or symptoms of severe cutaneous reactions occur, interrupt treatment until the etiology of the reaction has been determined.  Consultation with a dermatologist is recommended.  If SJS, TEN, or EM is confirmed, permanently discontinue alpelisib.  Do not reintroduce alpelisib in patients who have experienced previous severe cutaneous reactions during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5870, 0, 'Alpelisib', 'Diabetes Mellitus', 'Severe hyperglycemia, including ketoacidosis, has been reported in patients treated with alpelisib.  Before initiating treatment with alpelisib it is recommend to test, optimize and monitor blood glucose as clinically indicated.  Care should be exercised when using this agent in diabetic patients.  Patients with a history of diabetes mellitus may require intensified diabetic treatment.  Based on the severity of the hyperglycemia, alpelisib may require dose interruption, reduction, or discontinuation.  Advise patients of the signs and symptoms of hyperglycemia.  Closely monitor patients with diabetes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5871, 0, 'Alpelisib', 'Diarrhea', 'Severe diarrhea, including dehydration and acute kidney injury, occurred in patients treated with alpelisib.  Based on the severity of the diarrhea, alpelisib may require dose interruption, reduction, or discontinuation.  Care should be exercised when using this agent in patients with diarrhea.  Advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs while taking alpelisib.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5872, 0, 'Alpelisib', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ) has been reported in patients using alpelisib.  Caution is advised when this drug and bisphosphonates or denosumab are used either simultaneously or sequentially.  Do not initiate treatment with alpelisib in patients with ongoing osteonecrosis of the jaw from previous or concurrent treatment with bisphosphonates or denosumab.  Patients experiencing ONJ should be managed according to clinical practice.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5873, 0, 'Alpelisib', 'Pneumonia', 'Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, has been reported in patients treated with alpelisib.  It is recommended to interrupt alpelisib immediately and evaluate the patient for pneumonitis in patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis.  Advise patients to immediately report new or worsening respiratory symptoms.  Permanently discontinue alpelisib in all patients with confirmed pneumonitis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5874, 0, 'Alpelisib', 'Kidney Diseases', 'No dose adjustment is recommended for patients with mild to moderate renal impairment (CrCl 30 to < 90 mL/min).  Close monitoring is recommended when using alpelisib in patients with severe renal impairment (CrCl < 30 mL/min) as its effect on the pharmacokinetics is unknown.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5875, 0, 'Dextropropoxyphene', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5876, 0, 'Dextropropoxyphene', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5877, 0, 'Dextropropoxyphene', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5878, 0, 'Dextropropoxyphene', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5879, 0, 'Dextropropoxyphene', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5880, 0, 'Dextropropoxyphene', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5881, 0, 'Dextropropoxyphene', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5882, 0, 'Dextropropoxyphene', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5883, 0, 'Dextropropoxyphene', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5884, 0, 'Dextropropoxyphene', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5885, 0, 'Dextropropoxyphene', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5886, 0, 'Dextropropoxyphene', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5887, 0, 'Dextropropoxyphene', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5888, 0, 'Dextropropoxyphene', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5889, 0, 'Dextropropoxyphene', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5890, 0, 'Dextropropoxyphene', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5891, 0, 'Dextropropoxyphene', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5892, 0, 'Diazoxide', 'Arrhythmias, Cardiac', 'The use of diazoxide is associated with compensatory tachycardia.  Therapy with diazoxide should be administered cautiously in patients with tachycardia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5893, 0, 'Diazoxide', 'Heart Failure', 'Diazoxide may lead to significant fluid retention, which may precipitate congestive heart failure in patients with impaired cardiac reserve.  The fluid retention will respond to conventional therapy with diuretics.  Therapy with diazoxide should be administered cautiously in patients with congestive heart failure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5894, 0, 'Diazoxide', 'Gout', 'Diazoxide can increase serum uric acid levels due to decreased excretion.  This should be kept in mind, particularly in patients with hyperuricemia or a history of gout.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5895, 0, 'Diazoxide', 'Hypertension, Pulmonary', 'There have been postmarketing reports of pulmonary hypertension in infants and neonates treated with diazoxide.  The cases were reversible upon discontinuation of the drug.  Patients should be carefully monitored, especially those with risk factors for pulmonary hypertension, or respiratory distress.  Diazoxide should be discontinued if pulmonary hypertension is suspected.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5896, 0, 'Diazoxide', 'Kidney Diseases', 'The plasma half-life of diazoxide is prolonged in patients with impaired renal function.  A reduced dosage should be considered.  Serum electrolyte levels should also be evaluated for such patients.  Caution and monitoring is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5897, 0, 'Diazepam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5898, 0, 'Diazepam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5899, 0, 'Diazepam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5900, 0, 'Diazepam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5901, 0, 'Diazepam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5902, 0, 'Diazepam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5903, 0, 'Diazepam', 'Hypotension', 'Benzodiazepines should not be administered by injection to patients in shock or coma.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5904, 0, 'Diazepam', 'Myasthenia Gravis', 'The use of diazepam is contraindicated in patients with myasthenia gravis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5905, 0, 'Diazepam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5906, 0, 'Diazepam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5907, 0, 'Diazepam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5908, 0, 'Diclofenac (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5909, 0, 'Diclofenac (ophthalmic)', 'Blood Platelet Disorders', 'Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals.  These effects may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5910, 0, 'Diclofenac (topical)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5911, 0, 'Diclofenac (topical)', 'Kidney Diseases', 'No information is available from controlled clinical trials regarding the use of topical diclofenac in patients with advanced renal disease.  Therefore, treatment with this drug is not recommended in patients with advanced renal disease.  If therapy with topical diclofenac is initiated, close monitoring of the patient''s renal function is advisable.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5912, 0, 'Diclofenac (topical)', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5913, 0, 'Diclofenac (topical)', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5914, 0, 'Diclofenac (topical)', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5915, 0, 'Diclofenac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5916, 0, 'Diclofenac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5917, 0, 'Diclofenac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5918, 0, 'Diclofenac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5919, 0, 'Diclofenac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5920, 0, 'Diclofenac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5921, 0, 'Diclofenac', 'Porphyrias', 'There has been an isolated report associating the use of diclofenac with precipitation of a porphyria attack.  The proposed mechanism, demonstrated in rats, is through stimulation by diclofenac (and possibly other nonsteroidal anti-inflammatory agents) of the porphyrin precursor, delta-aminolevulinic acid.  The manufacturer recommends avoiding diclofenac in patients with hepatic porphyria.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5922, 0, 'Diclofenac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5923, 0, 'Diclofenac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5924, 0, 'Diclofenac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5925, 0, 'Diclofenac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5926, 0, 'Diclofenac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5927, 0, 'Diclofenac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5928, 0, 'Alprazolam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5929, 0, 'Alprazolam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5930, 0, 'Alprazolam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5931, 0, 'Alprazolam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5932, 0, 'Alprazolam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5933, 0, 'Alprazolam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5934, 0, 'Alprazolam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5935, 0, 'Alprazolam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5936, 0, 'Alprazolam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5937, 0, 'Diflunisal', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5938, 0, 'Diflunisal', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5939, 0, 'Diflunisal', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5940, 0, 'Diflunisal', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5941, 0, 'Diflunisal', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5942, 0, 'Diflunisal', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5943, 0, 'Diflunisal', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5944, 0, 'Diflunisal', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5945, 0, 'Diethylpropion', 'Cardiovascular Diseases', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism.  Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure.  Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use.  In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities.  In general, amphetamines should not be used in patients with structural cardiac abnormalities.  If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5946, 0, 'Diethylpropion', 'Glaucoma', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  Like other sympathomimetic amines, amphetamines can induce transient mydriasis.  In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma.  If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5947, 0, 'Diethylpropion', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5948, 0, 'Diethylpropion', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5949, 0, 'Diethylpropion', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5950, 0, 'Diethylpropion', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5951, 0, 'Diethylpropion', 'Hypertension, Pulmonary', 'The use of some CNS stimulants has been associated with an increased risk of developing pulmonary hypertension, a rare but fatal disorder.  The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension.  Under these circumstances, treatment must be immediately discontinued, and the patient should be evaluated to confirm diagnosis.  Caution should be exercised in patients with preexisting valvular heart disease or history of pulmonary hypertension.  These drugs are not recommended in patients with known heart murmur or valvular heart disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5952, 0, 'Diethylpropion', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5953, 0, 'Diethylpropion', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5954, 0, 'Diethylpropion', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5955, 0, 'Diethylpropion', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5956, 0, 'Diethylpropion', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5957, 0, 'Diethylpropion', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5958, 0, 'Diethylpropion', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5959, 0, 'Digoxin', 'Wolff-Parkinson-White Syndrome', 'Digoxin may enhance accessory pathway conduction in conditions such as the Wolff-Parkinson-White syndrome.  Patients with Wolf-Parkinson-White syndrome that presents atrial fibrillation are at higher risk for ventricular fibrillation.  Treatment with digoxin should be used with caution in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5960, 0, 'Digoxin', 'Atrioventricular Block', 'Digoxin slows sinoatrial and AV conduction, prolonging the PR interval.  When treated with digoxin, patients with preexisting sinus node disease may develop severe sinus bradycardia or sinoatrial block, and patients with incomplete AV block may progress to advanced or complete heart block.  In such patients, consideration should be given to the insertion of a pacemaker prior to initiating treatment with digoxin.  Digoxin may be administered to patients with complete, stable AV block who have congestive heart failure, provided the block was not induced by cardiac glycosides.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5961, 0, 'Digoxin', 'Hypercalcemia', 'Calcium and digoxin have additive inotropic effects.  Therefore, hypercalcemia from any cause will predispose patients to digoxin toxicity and serious arrhythmias.  Hypercalcemia should be corrected prior to initiating treatment with digoxin, and serum calcium levels should be monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5962, 0, 'Digoxin', 'Hypocalcemia', 'Hypocalcemia can nullify the effects of digoxin.  The drug may be ineffective in hypocalcemic patients until serum calcium levels are restored to normal.  Restore serum calcium levels prior to initiating therapy with digoxin to obtain maximum results when using digoxin.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5963, 0, 'Digoxin', 'Hypokalemia', 'Potassium and/or magnesium depletion sensitizes the myocardium to digoxin.  In patients with hypokalemia or hypomagnesemia, digoxin toxicity may occur despite serum drug concentrations below 2.0 ng/mL.  Therapy with digoxin should be administered cautiously in patients with or predisposed to potassium and/or magnesium deficiency, including patients on diuretic therapy; those with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; those with malnutrition; and renal dialysis patients.  Electrolyte imbalances should be corrected prior to initiation of treatment.  Serum potassium and magnesium concentrations should be monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5964, 0, 'Digoxin', 'Cardiovascular disease', 'Patients with heart failure associated with preserved left ventricular systolic function, such as in restrictive cardiomyopathy, constrictive pericarditis, amyloid heart disease and acute cor pulmonale, may be particularly susceptible to experience decrease cardiac output.  Therapy with digoxin should be administered cautiously in such patients.  Patients with idiopathic hypertrophic subaortic stenosis may have worsening of the outflow obstruction due to the inotropic effects of digoxin.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5965, 0, 'Digoxin', 'Kidney Diseases', 'Digoxin is primarily eliminated by the kidney.  Patients with renal impairment may be at increased risk for digoxin toxicity, including ventricular arrhythmias and AV conduction disturbances, due to decreased drug clearance.  Therapy with digoxin should be administered cautiously in patients with impaired renal function.  Dosage adjustments should be made according to product package labeling and patient attributes such as age, ideal body weight, and other concomitant disease states and medication usage.  Dosage increments should be made very gradually, since the elimination half-life may be prolonged in these patients and a longer period of time is required to establish steady-state serum concentrations than normal.  These patients should be monitored closely for manifestations of toxicity, and dosages further adjusted as necessary.  If toxicity occurs, clinicians should be aware that the adverse effects may also be prolonged.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5966, 0, 'Digoxin', 'Myocarditis', 'Digoxin can rarely precipitate vasoconstriction and may promote the development of cytokines; therefore, should be avoided in patients with myocarditis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5967, 0, 'Digoxin', 'Arrhythmias, Cardiac', 'The use of digoxin is contraindicated in patients with ventricular fibrillation.  Digoxin toxicity is associated with adverse cardiac effects, including ventricular arrhythmias, which are most commonly seen in chronic toxicity.  Digoxin-induced ventricular tachycardia is associated with a high mortality rate, since ventricular fibrillation or asystole may result.  Therapy with digoxin should be administered cautiously in patients with frequent ventricular premature contractions or ventricular tachycardia, especially if these arrhythmias are not caused by heart failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5968, 0, 'Digoxin', 'Myocardial Infarction', 'The use of inotropic drugs in some patients with acute myocardial infarction may lead to increases in myocardial oxygen demand and lead to ischemia.  Therapy with digoxin should be administered cautiously in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5969, 0, 'Digoxin', 'Hyperthyroidism', 'Heart failure and/or atrial arrhythmias resulting from hypermetabolic or hyperdynamic states such as hyperthyroidism, hypoxia, or arteriovenous shunt are best managed by treating the underlying condition.  Atrial arrhythmias associated with hypermetabolic states are particularly refractory to digoxin, possibly due to altered pharmacokinetics.  Specifically, the apparent volume of distribution and renal elimination of the drug may be increased, resulting in lower serum concentrations.  Therapy with digoxin should be administered cautiously in patients with hyperthyroidism.  Serum digoxin levels should be monitored regularly and dosage adjustments may be required secondary to changes in their thyroid condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5970, 0, 'Digoxin', 'Hypothyroidism', 'Hypothyroidism may reduce the requirements for digoxin due to decreased volume of distribution and plasma clearance of the drug.  Therapy with digoxin should be initiated at lower dosages in patients with hypothyroidism to avoid toxicity.  Serum digoxin levels should be monitored regularly and dosage adjustments may be required secondary to changes in thyroid condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5971, 0, 'Digoxin', 'Thiamine Deficiency', 'Patients with beri beri heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5972, 0, 'Diclofenamide', 'Acidosis', 'The use of dichlorphenamide is contraindicated acidotic patients (hyperchloremic or respiratory).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5973, 0, 'Diclofenamide', 'Adrenal Insufficiency', 'The use of dichlorphenamide is contraindicated in adrenocortical insufficiency.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5974, 0, 'Diclofenamide', 'Dehydration', 'The use of dichlorphenamide is contraindicated in patients with hyponatremia or hypokalemia, or in conditions in which serum levels of sodium or potassium are depressed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5975, 0, 'Diclofenamide', 'Liver Diseases', 'The use of dichlorphenamide is contraindicated in hepatic insufficiency.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5976, 0, 'Diclofenamide', 'Lung Diseases', 'Dichlorphenamide should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation as their acidosis may be increased.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5977, 0, 'Diclofenamide', 'Kidney Diseases', 'The use of dichlorphenamide is contraindicated in renal failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5978, 0, 'Diclofenamide', 'Acidosis, Respiratory', 'Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis.  Respiratory status should be monitored during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5979, 0, 'Diclofenamide', 'Diabetes Mellitus', 'Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus.  Routine glucose monitoring is recommended during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5980, 0, 'Diclofenamide', 'Gout', 'Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels return to normal when the drug is discontinued.  Monitoring of uric acid levels is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5981, 0, 'Alprostadil', 'Respiratory Distress Syndrome, Newborn', 'Alprostadil injection should not be used in neonates with respiratory distress syndrome.  Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with alprostadil injection.  Respiratory status should be monitored throughout treatment, and alprostadil injection should be used where ventilatory assistance is immediately available.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5982, 0, 'Alprostadil', 'Hemorrhage', 'Alprostadil inhibits platelet aggregation.  Caution is recommended when using alprostadil injection in neonates with bleeding tendencies.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5983, 0, 'Alprostadil', 'Hypotension', 'Increased peripheral blood levels of prostaglandin E1 (PGE1) and its metabolites can lead to hypotension and/or dizziness.  Intracavernous injections of alprostadil can lead to increased blood levels of PGE1.  Therapy with alprostadil should be administered cautiously in patients with hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5984, 0, 'Digoxin Immune Fab (Ovine)', 'Hypokalemia', 'Severe digitalis intoxication can result in life-threatening elevations of serum potassium as potassium is shifted from inside the cell to the serum.  Elevated serum potassium leads to increased renal elimination of potassium and can result in a total body deficit of potassium.  Hypokalemia may develop rapidly following digoxin immune Fab as potassium reenters the cells. Serum potassium concentrations should be monitored prior to, during and following digoxin immune Fab therapy and cautiously replaced as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5985, 0, 'Digoxin Immune Fab (Ovine)', 'Kidney Diseases', 'Digoxin immune Fab is eliminated by the kidney complexed to digoxin or digitoxin.  The elimination half-life of digoxin immune Fab has not been fully defined, however it is expected to be prolonged in patients with severe renal impairment.  It is uncertain if failure to eliminate the complex can lead to reintoxication following the release of complexed digoxin/digitoxin.  Therapy with digoxin immune Fab should be administered cautiously in patients with severe renal dysfunction.  Clinical monitoring of renal function and symptoms of toxicity should be monitored for an extended time.  Digoxin immune Fab interferes with digitalis immunoassay measurements.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5986, 0, 'Dicloxacillin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5987, 0, 'Dicloxacillin', 'Hematologic Diseases', 'The use of penicillinase-resistant penicillins has been associated with adverse hematologic effects, including neutropenia, leukopenia, granulocytopenia and thrombocytopenia, particularly when given in high parenteral dosages.  Agranulocytosis and prolonged bleeding time have been reported rarely.  Therapy with penicillinase-resistant penicillins should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow depression, and hematopoietic function should be monitored.  Blood counts with differential should be performed prior to initiation of therapy and 1 to 3 times weekly during therapy.  Hematologic abnormalities are generally reversible and resolve within several days to two weeks following discontinuation of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5988, 0, 'Dicloxacillin', 'Cystic Fibrosis', 'The penicillinase-resistant penicillins, dicloxacillin and methicillin, are both eliminated by the kidney.  Renal elimination of these penicillins has been shown to increase in patients with cystic fibrosis, resulting in decreased peak serum drug concentrations and AUCs.  Clinicians should be cognizant of these effects when prescribing or administering the antibiotics to patients with cystic fibrosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5989, 0, 'Dicloxacillin', 'Heart Failure', 'Each 250 mg capsule of dicloxacillin sodium contains approximately 14 mg (0.6 mEq) of sodium, and each teaspoonful of the 62.5 mg/5 mL oral suspension contains approximately 67 mg (2.9 mEq) of sodium.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5990, 0, 'Dicyclomine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5991, 0, 'Dicyclomine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5992, 0, 'Dicyclomine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5993, 0, 'Dicyclomine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5994, 0, 'Dicyclomine', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5995, 0, 'Dicyclomine', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5996, 0, 'Dicyclomine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5997, 0, 'Dicyclomine', 'Hemorrhage', 'Therapy with dicyclomine is contraindicated in patients with unstable cardiovascular status in acute hemorrhage.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5998, 0, 'Dicyclomine', 'Esophagitis, Peptic', 'Therapy with dicyclomine is contraindicated in patients with reflux esophagitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5999, 0, 'Dicyclomine', 'Colitis, Ulcerative', 'Therapy with dicyclomine is contraindicated in patients with severe ulcerative colitis.  Antimuscarinic agents, such as dicyclomine may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  Antimuscarinic agents should be administered cautiously to patients with ulcerative colitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6000, 0, 'Dicyclomine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', 'DDInter');
